Skip to main content

CORRECTION article

Front. Immunol., 21 April 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.887775
This article is part of the Research Topic New Horizons in Tumor Microenvironment Biology and Therapy: Implications for New Therapies, Volume II View all 18 articles

Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy

This article is a correction to:

  1. Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy

    1. Read original article
Xueting Wan,&#x;Xueting Wan1,2†Mengyao Song,&#x;Mengyao Song1,2†Aiyun Wang,,Aiyun Wang1,2,3Yang Zhao,,Yang Zhao1,2,4Zhonghong Wei,*Zhonghong Wei1,2*Yin Lu,,*Yin Lu1,2,3*
  • 1Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
  • 2Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine, Nanjing, China
  • 3Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China
  • 4Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China

A Corrigendum on:
Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy

By Wan X, Song M, Wang A, Zhao Y, Wei Z and Lu Y (2021) Front. Immunol. 12:747914. doi: 10.3389/fimmu.2021.747914

In the published article, there was an error in affiliation 3. Instead of “Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing, China”, it should be “Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: microbiome, immunotherapy, immune checkpoint, angiogenesis, prebiotics, Chinese medicine

Citation: Wan X, Song M, Wang A, Zhao Y, Wei Z and Lu Y (2022) Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy. Front. Immunol. 13:887775. doi: 10.3389/fimmu.2022.887775

Received: 02 March 2022; Accepted: 01 April 2022;
Published: 21 April 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Wan, Song, Wang, Zhao, Wei and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yin Lu, luyingreen@njucm.edu.cn; Zhonghong Wei, wzh1225@njucm.edu.cn

†These authors contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.